Header Unit

Breaking News: PrEP for STDs

Imstilljosh.com has confirmed from sources that PrEP for STDs works.

This developing story is confirmed via multiple sources and the news that a pilot study of: “PrEP for Syphilis” among HIV-positive MSM (men who have sex with men) will release Tuesday.


Follow David Heitz on Twitter and Facebook.


PrEP (Pre-Exposure Prophylaxis) for HIV has been the focal point of health advocates for the prevention of HIV for the better part of last year or so, but one major argument and cause of contention from opponents is: the lack of protection against other sexually transmitted diseases and infections.

Learn More About PrEP:  LGBT PrEP Guide for HIV Prevention

This story is developing and imstilljosh.com will update it as news becomes available and official word is released this coming week.

David Heitz, a nationally recognized health journalist for his fact-based health reporting, will publish an article all about this huge development with imstilljosh.com on Tuesday.

6 Comments Join the Conversation →

  1. JamesFBarry

    OMG????? Now that is good news……..

  2. Jeton Ademaj

    what’s he on? i’ve been on minocycline since 2005 and azithromycin since 2010, and with my perfect adherence i have little fear of syph, gono or clap…and have noted this in my online profiles for years.

  3. Mark S. King

    Good lord, what’s next? Gay men having sex without condoms because there are treatments to prevent acquiring STD’s? How are we supposed to feel ashamed of our every sexual move if we can’t be trashed and cautioned and have fingers pointed at us? Quick, somebody come up with another risk of gay sex. Carpel tunnel? Back spasms?

  4. Mark Hubbard

    Here’s balanced coverage of the issue from one of the best HIV writers in the business:

    Pilot study suggests that PrEP for other STIs might work


    Note the responsible headline. A pilot study does not provide a definitive answer, but provides guidance on whether a larger, potentially definitive study is feasible.

    “There were 76% fewer cases of syphilis [vs. an intervention using a financial incentive to avoid STIs], although the small size of the study meant that this
    difference was not statistically significant.”

    “The authors suggest that “the use of daily doxycycline
    against syphilis would.be an appropriate prevention tool…for a relatively small
    yet epidemiologically important population” of gay men. They add that the 77%
    overall retention rate in the pilot study “suggests that a clinical trial in a
    persistently high-risk group” of HIV-positive gay men “is feasible”.

    It’s important to note that resistance concerns are much higher when using PrEP for STIs because the infections involved are much more common and much more transmissible, and because the PrEP drug is much less narrowly purposed – i.e. much more widely used for a variety of infections.

    An accompanying editorial observes:

    “Long-term use of doxycycline is likely to promote resistance in patients’ endogenous microbial flora and could lead to more widespread doxycycline resistance in MSM. Although we agree with the authors that this issue may not be critical for currently identified STI pathogens, the effect on bacteria like Staphylococcus aureus, Streptococcus pneumoniae, enterococci, coliforms, and other bacteria may be important. On the other hand, depending on how narrowly clinicians target their use of STI PrEP, the population impact might be limited.

    The investigators’ goal in undertaking the current study was to define the feasibility and potential value of a larger trial. Sexually transmitted infection PrEP has high biological plausibility, and the trial’s success in enrolling patients and achieving a high level of patient adherence is convincing that such a trial is feasible. However, to us it seems premature to commit the substantial resources such a trial would require; a number of questions need to be addressed first. At a minimum, these should include literature reviews and consultations to estimate the potential individual-level benefits and risks associated with STI PrEP, including but not limited to microbiome effects and the individual health implications of those effects; dynamic mathematical modeling to estimate the potential population-level risk and benefits of the intervention, including cost effectiveness; and community consultations to assess the candidate population’s willingness to accept risk related to STI PrEP and the value its members place on averting STI, particularly asymptomatic or readily treatable STIs.

    Although we have misgivings about STI PrEP as an intervention at this time, Bolan and his colleagues deserve credit and our collective thanks for creative thinking. STI among MSM is among the most pressing issues facing our field.We need to think more deeply about what our goals are in terms of STI prevention in MSM, and we need to try new things. Creativity is in short supply, and we need to be open to new ideas.”

Comments are closed.